Literature DB >> 8200252

Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

H S Brand1, M A Maas, A Bosma, R J Van Ketel, P Speelman, R A Chamuleau.   

Abstract

In three experimental models in rats, surgical construction of a self-filling blind loop (SFBL), trinitrobenzene sulfonic acid (TNB) -induced colitis, and the combination of SFBL and TNB, the hypothesis was studied that intestine-derived endotoxins play a role in the pathogenesis of hepatobiliary disorders in chronic inflammatory bowel disease (CIBD). After eight weeks of treatment, a mild increase in portal and systemic endotoxin levels and interleukin-6 concentrations was observed and the serum levels of alkaline phosphatase, bilirubin, and ALAT were only mildly increased in SFBL plus TNB rats. Histopathological examination of the liver showed hardly any abnormalities in all three rat models. These results show that low-grade portal and systemic endotoxinemia in rats, induced by bacterial overgrowth and/or chemical colitis, is not able to induce hepatobiliary alterations. To exclude definitively a possible role for portal endotoxinemia in the pathogenesis of CIBD-associated hepatobiliary abnormalities, however, an adequate animal model for CIBD is urgently needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200252     DOI: 10.1007/bf02093785

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Hepatic mechanisms for clearance and detoxification of bacterial endotoxins.

Authors:  E S Fox; P Thomas; S A Broitman
Journal:  J Nutr Biochem       Date:  1990-12       Impact factor: 6.048

Review 2.  Liver lesions in inflammatory bowel disorders.

Authors:  V J Desmet; K Geboes
Journal:  J Pathol       Date:  1987-04       Impact factor: 7.996

Review 3.  Advances in primary sclerosing cholangitis.

Authors:  K D Lindor; R H Wiesner; R L MacCarty; J Ludwig; N F LaRusso
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

Review 4.  Hepatobiliary complications of inflammatory bowel disease.

Authors:  S M Williams; R K Harned
Journal:  Radiol Clin North Am       Date:  1987-01       Impact factor: 2.303

5.  Sclerosing cholangitis in ulcerative colitis.

Authors:  E Schrumpf; K Elgjo; O Fausa; E Gjone; F Kolmannskog; S Ritland
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

6.  Biliary tract disease in rats with experimental small bowel bacterial overgrowth.

Authors:  S N Lichtman; J Keku; R L Clark; J H Schwab; R B Sartor
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

Review 7.  Pathogenesis of sclerosing cholangitis: the role of nonimmune factors.

Authors:  S Sherlock
Journal:  Semin Liver Dis       Date:  1991-02       Impact factor: 6.115

8.  The relationship between plasma free fatty acids and experimentally induced hepatic encephalopathy in the rat.

Authors:  J J Smit; D K Bosman; G G Jörning; J G de Haan; M A Maas; R A Chamuleau
Journal:  Clin Chim Acta       Date:  1991-03-15       Impact factor: 3.786

9.  Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth.

Authors:  S N Lichtman; J Keku; J H Schwab; R B Sartor
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

10.  The rectal mucosa-associated microflora in patients with ulcerative colitis.

Authors:  M G Hartley; M J Hudson; E T Swarbrick; M J Hill; A E Gent; M D Hellier; R H Grace
Journal:  J Med Microbiol       Date:  1992-02       Impact factor: 2.472

View more
  2 in total

1.  Influence of modest endotoxemia on postoperative antithrombin deficiency and circulating secretory immunoglobulin a levels.

Authors:  Tetsuji Fujita; Takashi Imai; Sadao Anazawa
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

2.  Experimental colitis attenuates development of toxin-induced cholangitis in rats.

Authors:  Kartika Tjandra; Tai Le; Mark G Swain
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.